BioCryst Pharmaceuticals (BCRX) Stock Forecast, Price Target & Predictions
BCRX Stock Forecast
BioCryst Pharmaceuticals stock forecast is as follows: an average price target of $16.00 (represents a 101.01% upside from BCRX’s last price of $7.96) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.
BCRX Price Target
The average price target for BioCryst Pharmaceuticals (BCRX) is $16.00 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $25.00 to $7.00. This represents a potential 101.01% upside from BCRX's last price of $7.96.
BCRX Analyst Ratings
According to 14 Wall Street analysts, BioCryst Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for BCRX stock is 0 'Strong Buy' (0.00%), 11 'Buy' (78.57%), 3 'Hold' (21.43%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
BioCryst Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 06, 2024 | Gena Wang | Barclays | $7.00 | $7.51 | -6.79% | -12.06% |
| Aug 05, 2024 | Maury Raycroft | Jefferies | $11.00 | $7.51 | 46.47% | 38.19% |
| Nov 02, 2022 | Liisa Bayko | Evercore ISI | $16.00 | $12.38 | 29.19% | 101.01% |
| Aug 23, 2022 | Gena Wang | Barclays | $14.00 | $14.32 | -2.27% | 75.88% |
| Jan 10, 2022 | Ken Cacciatore | Cowen & Co. | $25.00 | $14.78 | 69.15% | 214.07% |
| Nov 03, 2021 | Brian Cheng | Cantor Fitzgerald | $21.00 | $12.40 | 69.35% | 163.82% |
| Aug 09, 2021 | Maury Raycroft | Jefferies | $19.00 | $17.65 | 7.65% | 138.69% |
The latest BioCryst Pharmaceuticals stock forecast, released on Aug 06, 2024 by Gena Wang from Barclays, set a price target of $7.00, which represents a -6.79% decrease from the stock price at the time of the forecast ($7.51), and a -12.06% decrease from BCRX last price ($7.96).
BioCryst Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 2 |
| Avg Price Target | - | $9.00 | $9.00 |
| Last Closing Price | $7.96 | $7.96 | $7.96 |
| Upside/Downside | -100.00% | 13.07% | 13.07% |
In the current month, the average price target of BioCryst Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to BioCryst Pharmaceuticals's last price of $7.96. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 06, 2024 | JMP Securities | Outperform | Outperform | Hold |
| Aug 06, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Aug 05, 2024 | Jefferies | Buy | Buy | Hold |
| Jun 25, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 07, 2024 | JMP Securities | Outperform | Outperform | Hold |
| Sep 18, 2023 | RBC Capital | - | Outperform | Upgrade |
| Aug 04, 2023 | Wolfe Research | Underperform | Outperform | Upgrade |
| Aug 04, 2023 | Janney Montgomery | - | Buy | Upgrade |
| Aug 04, 2023 | Raymond James | Market Perform | Outperform | Upgrade |
| Aug 04, 2023 | William Blair | - | Market Perform | Downgrade |
BioCryst Pharmaceuticals's last stock rating was published by JMP Securities on Aug 06, 2024. The company gave BCRX a "Outperform" rating, the same as its previous rate.
BioCryst Pharmaceuticals Financial Forecast
BioCryst Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $86.74M | $82.49M | $68.78M | $79.55M | $75.83M | - | $49.92M | $47.16M | $40.99M | $49.96M | $19.06M | $4.02M | $6.10M | $2.87M | $4.82M | $39.73M | $1.77M | $1.45M | $5.89M | $1.45M | $12.49M |
| Avg Forecast | $144.74M | $133.04M | $123.80M | $112.25M | $116.48M | $112.56M | $98.30M | $85.62M | $89.97M | $86.06M | $81.42M | $71.69M | $75.23M | $74.78M | $63.33M | $51.36M | $51.06M | $40.20M | $28.11M | $8.83M | $14.74M | $3.60M | $2.25M | $4.29M | $9.88M | $2.96M | $2.02M | $3.11M | $1.35M | $15.78M |
| High Forecast | $148.60M | $136.59M | $127.11M | $115.25M | $119.59M | $116.29M | $100.93M | $87.90M | $94.32M | $88.36M | $83.59M | $73.60M | $77.23M | $76.78M | $63.33M | $52.58M | $52.28M | $41.15M | $28.78M | $9.04M | $15.09M | $3.69M | $2.31M | $4.39M | $10.11M | $3.03M | $2.07M | $3.18M | $1.62M | $18.94M |
| Low Forecast | $130.72M | $120.15M | $111.81M | $101.37M | $105.20M | $103.23M | $88.78M | $77.32M | $86.55M | $77.72M | $73.53M | $64.74M | $67.94M | $67.54M | $63.33M | $50.03M | $49.74M | $39.16M | $27.38M | $8.60M | $14.36M | $3.51M | $2.19M | $4.18M | $9.62M | $2.89M | $1.97M | $3.03M | $1.08M | $12.63M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 18 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.01% | 1.01% | 0.96% | 1.06% | 1.01% | - | 0.97% | 0.92% | 1.02% | 1.78% | 2.16% | 0.27% | 1.69% | 1.27% | 1.12% | 4.02% | 0.60% | 0.72% | 1.89% | 1.08% | 0.79% |
BioCryst Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 7 analysts is $89.97M, with a low forecast of $86.55M, and a high forecast of $94.32M. BCRX's average Quarter revenue forecast represents a 3.72% increase compared to the company's last Quarter revenue of $86.74M (Sep 23).
BioCryst Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 18 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-7.74M | $-16.95M | $-25.04M | $-43.61M | $-15.69M | - | $-49.90M | $3.42M | $-44.46M | $-29.50M | $-51.20M | $-54.70M | $-42.71M | $-35.51M | $-34.33M | $650.00K | $-34.37M | $-34.41M | $-28.15M | $-27.06M | $-16.06M |
| Avg Forecast | $-111.08M | $-102.10M | $-95.01M | $-86.14M | $-89.39M | $-86.38M | $-75.44M | $-29.84M | $-69.04M | $-66.04M | $-62.48M | $-31.92M | $-57.73M | $-50.61M | $-48.60M | $-39.41M | $5.14M | $-40.01M | $-26.82M | $-34.13M | $-35.01M | $-41.00M | $-36.93M | $-34.33M | $-7.58M | $-32.22M | $-31.08M | $-27.11M | $-24.97M | $-19.41M |
| High Forecast | $-100.31M | $-92.21M | $-85.80M | $-77.80M | $-80.73M | $-79.22M | $-68.13M | $-23.87M | $-66.42M | $-59.64M | $-56.43M | $-25.53M | $-52.14M | $-40.49M | $-48.60M | $-38.40M | $6.17M | $-32.01M | $-21.46M | $-27.31M | $-28.01M | $-32.80M | $-29.54M | $-27.47M | $-7.38M | $-25.77M | $-24.87M | $-21.69M | $-19.98M | $-15.52M |
| Low Forecast | $-114.04M | $-104.82M | $-97.54M | $-88.44M | $-91.78M | $-89.25M | $-77.45M | $-35.81M | $-72.38M | $-67.81M | $-64.15M | $-38.30M | $-59.27M | $-60.74M | $-48.60M | $-40.35M | $4.11M | $-48.01M | $-32.19M | $-40.96M | $-42.01M | $-49.20M | $-44.31M | $-41.20M | $-7.76M | $-38.66M | $-37.30M | $-32.53M | $-29.97M | $-23.29M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.12% | 0.27% | 0.78% | 0.76% | 0.31% | - | 1.27% | 0.67% | 1.11% | 1.10% | 1.50% | 1.56% | 1.04% | 0.96% | 1.00% | -0.09% | 1.07% | 1.11% | 1.04% | 1.08% | 0.83% |
3 analysts predict BCRX's average Quarter EBITDA for Mar 22 to be $-39.41M, with a high of $-38.40M and a low of $-40.35M. This is -1250.78% lower than BioCryst Pharmaceuticals's previous annual EBITDA (Dec 21) of $3.42M.
BioCryst Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 18 |
| Net Income | - | - | - | - | - | - | - | - | - | $-36.15M | $-75.33M | $-53.33M | $-71.54M | $-42.52M | - | $-74.20M | $-17.78M | $-58.80M | $-43.20M | $-64.28M | $-60.49M | $-46.12M | $-38.61M | $-37.60M | $-2.62M | $-37.59M | $-37.63M | $-31.05M | $-29.60M | $-18.45M |
| Avg Forecast | $-1.03M | $-8.26M | $-14.45M | $-22.71M | $-18.37M | $-16.72M | $-35.71M | $-37.47M | $-50.75M | $-50.57M | $-48.30M | $-40.07M | $-34.34M | $-66.94M | $-70.81M | $-73.01M | $-26.67M | $-52.92M | $-39.27M | $-42.86M | $-38.72M | $-44.27M | $-40.15M | $-37.60M | $-51.70M | $-35.24M | $-33.99M | $-29.90M | $-27.32M | $-22.29M |
| High Forecast | $-902.11K | $-7.22M | $-12.63M | $-19.85M | $-16.06M | $-7.17M | $-31.21M | $-29.97M | $-29.61M | $-44.20M | $-42.22M | $-32.06M | $-30.01M | $-53.56M | $-70.81M | $-70.56M | $-21.33M | $-42.34M | $-31.42M | $-34.28M | $-30.97M | $-35.42M | $-32.12M | $-30.08M | $-49.96M | $-28.19M | $-27.19M | $-23.92M | $-21.86M | $-17.83M |
| Low Forecast | $-1.07M | $-8.54M | $-14.95M | $-23.50M | $-19.01M | $-21.50M | $-36.95M | $-44.96M | $-80.36M | $-52.33M | $-49.98M | $-48.08M | $-35.53M | $-80.33M | $-70.81M | $-75.27M | $-32.00M | $-63.51M | $-47.13M | $-51.43M | $-46.46M | $-53.12M | $-48.18M | $-45.12M | $-53.30M | $-42.29M | $-40.78M | $-35.88M | $-32.78M | $-26.75M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.71% | 1.56% | 1.33% | 2.08% | 0.64% | - | 1.02% | 0.67% | 1.11% | 1.10% | 1.50% | 1.56% | 1.04% | 0.96% | 1.00% | 0.05% | 1.07% | 1.11% | 1.04% | 1.08% | 0.83% |
BioCryst Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BCRX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
BioCryst Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 18 |
| SG&A | - | - | - | - | - | - | - | - | - | $50.65M | $51.00M | $47.87M | $50.15M | $36.92M | - | $34.28M | $35.39M | $34.99M | $26.32M | $22.11M | $20.99M | $17.20M | $13.88M | $15.87M | $10.49M | $11.73M | $8.66M | $6.24M | $7.92M | $9.49M |
| Avg Forecast | $190.00M | $174.65M | $162.52M | $147.35M | $152.91M | $147.77M | $129.05M | $12.89M | $118.11M | $112.97M | $106.88M | $13.78M | $98.75M | $39.84M | $83.13M | $67.42M | $67.03M | $31.49M | $23.93M | $11.59M | $13.43M | $4.73M | $2.96M | $5.63M | $12.96M | $3.89M | $2.65M | $4.08M | $1.77M | $11.47M |
| High Forecast | $195.08M | $179.31M | $166.86M | $151.29M | $156.99M | $152.66M | $132.49M | $15.47M | $123.81M | $115.99M | $109.73M | $16.54M | $101.39M | $47.81M | $83.13M | $69.03M | $68.63M | $37.79M | $28.72M | $11.86M | $16.12M | $4.84M | $3.03M | $5.77M | $13.27M | $3.98M | $2.71M | $4.18M | $2.13M | $13.76M |
| Low Forecast | $171.59M | $157.73M | $146.77M | $133.08M | $138.10M | $135.52M | $116.54M | $10.31M | $113.62M | $102.03M | $96.52M | $11.03M | $89.18M | $31.87M | $83.13M | $65.68M | $65.30M | $25.19M | $19.15M | $11.29M | $10.74M | $4.61M | $2.88M | $5.49M | $12.63M | $3.79M | $2.58M | $3.98M | $1.42M | $9.18M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.45% | 0.48% | 3.47% | 0.51% | 0.93% | - | 0.51% | 0.53% | 1.11% | 1.10% | 1.91% | 1.56% | 3.63% | 4.69% | 2.82% | 0.81% | 3.02% | 3.27% | 1.53% | 4.47% | 0.83% |
BioCryst Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $118.11M, based on 7 Wall Street analysts, with a range of $113.62M to $123.81M. The forecast indicates a 133.19% rise compared to BCRX last annual SG&A of $50.65M (Sep 23).
BioCryst Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 18 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | - | $-0.40 | $-0.10 | $-0.33 | $-0.24 | $-0.36 | $-0.34 | $-0.26 | $-0.24 | $-0.24 | $-0.02 | $-0.34 | $-0.34 | $-0.28 | $-0.28 | $-0.19 |
| Avg Forecast | $-0.01 | $-0.04 | $-0.07 | $-0.11 | $-0.09 | $-0.08 | $-0.17 | $-0.21 | $-0.25 | $-0.24 | $-0.23 | $-0.30 | $-0.17 | $-0.29 | $-0.34 | $-0.36 | $-0.29 | $-0.29 | $-0.23 | $-0.27 | $-0.25 | $-0.26 | $-0.26 | $-0.24 | $-0.26 | $-0.32 | $-0.31 | $-0.27 | $-0.24 | $-0.29 |
| High Forecast | $-0.00 | $-0.03 | $-0.06 | $-0.10 | $-0.08 | $-0.03 | $-0.15 | $-0.18 | $-0.14 | $-0.21 | $-0.20 | $-0.26 | $-0.15 | $-0.25 | $-0.34 | $-0.35 | $-0.29 | $-0.28 | $-0.23 | $-0.26 | $-0.24 | $-0.25 | $-0.25 | $-0.23 | $-0.25 | $-0.31 | $-0.30 | $-0.26 | $-0.19 | $-0.23 |
| Low Forecast | $-0.01 | $-0.04 | $-0.07 | $-0.11 | $-0.09 | $-0.10 | $-0.18 | $-0.22 | $-0.39 | $-0.25 | $-0.24 | $-0.31 | $-0.17 | $-0.30 | $-0.34 | $-0.37 | $-0.30 | $-0.30 | $-0.24 | $-0.28 | $-0.26 | $-0.26 | $-0.26 | $-0.25 | $-0.26 | $-0.33 | $-0.32 | $-0.28 | $-0.29 | $-0.35 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.78% | 1.71% | 0.94% | 2.28% | 0.81% | - | 1.10% | 0.33% | 1.13% | 1.03% | 1.35% | 1.35% | 1.02% | 0.94% | 0.99% | 0.08% | 1.06% | 1.10% | 1.03% | 1.17% | 0.66% |
According to undefined Wall Street analysts, BioCryst Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BCRX previous annual EPS of $NaN (undefined).
BioCryst Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KZR | Kezar Life Sciences | $0.58 | $17.50 | 2917.24% | Buy |
| XFOR | X4 Pharmaceuticals | $0.70 | $3.67 | 424.29% | Buy |
| INMB | INmune Bio | $5.19 | $22.00 | 323.89% | Buy |
| PDSB | PDS Bio | $3.07 | $9.00 | 193.16% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.79 | $38.80 | 181.36% | Buy |
| IMUX | Immunic | $1.79 | $5.00 | 179.33% | Buy |
| APLS | Apellis Pharmaceuticals | $35.63 | $75.38 | 111.56% | Buy |
| BCRX | BioCryst Pharmaceuticals | $7.96 | $16.00 | 101.01% | Buy |
| AVXL | Anavex Life Sciences | $5.50 | $11.00 | 100.00% | Buy |
| VKTX | Viking Therapeutics | $64.45 | $100.50 | 55.93% | Buy |
| MDGL | Madrigal Pharmaceuticals | $233.16 | $315.75 | 35.42% | Buy |
| ATRA | Atara Biotherapeutics | $7.87 | $10.50 | 33.42% | Sell |
| AXSM | Axsome Therapeutics | $91.54 | $117.83 | 28.72% | Buy |
| MCRB | Seres Therapeutics | $1.05 | $1.25 | 19.05% | Buy |
| BPMC | Blueprint Medicines | $89.33 | $101.50 | 13.62% | Buy |
| TGTX | TG Therapeutics | $25.25 | $26.40 | 4.55% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
BCRX Forecast FAQ
Is BioCryst Pharmaceuticals a good buy?
Yes, according to 14 Wall Street analysts, BioCryst Pharmaceuticals (BCRX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 11 'Buy' recommendations, accounting for 78.57% of BCRX's total ratings.
What is BCRX's price target?
BioCryst Pharmaceuticals (BCRX) average price target is $16 with a range of $7 to $25, implying a 101.01% from its last price of $7.96. The data is based on 14 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will BioCryst Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for BCRX stock, the company can go up by 101.01% (from the last price of $7.96 to the average price target of $16), up by 214.07% based on the highest stock price target, and down by -12.06% based on the lowest stock price target.
Can BioCryst Pharmaceuticals stock reach $12?
BCRX's average twelve months analyst stock price target of $16 supports the claim that BioCryst Pharmaceuticals can reach $12 in the near future.
What are BioCryst Pharmaceuticals's analysts' financial forecasts?
BioCryst Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $412.97M (high $424.72M, low $374.53M), average EBITDA is $-281M (high $-252M, low $-294M), average net income is $-108M (high $-84.41M, low $-122M), average SG&A $442.62M (high $457.61M, low $400.47M), and average EPS is $-0.552 (high $-0.447, low $-0.592). BCRX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $513.83M (high $527.55M, low $464.05M), average EBITDA is $-394M (high $-356M, low $-405M), average net income is $-46.446M (high $-40.595M, low $-48.058M), average SG&A $674.53M (high $692.53M, low $609.17M), and average EPS is $-0.225 (high $-0.197, low $-0.233).
Did the BCRX's actual financial results beat the analysts' financial forecasts?
Based on BioCryst Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $331.41M, beating the average analysts forecast of $329.13M by 0.69%. Apple's EBITDA was $-104M, missing the average prediction of $-229M by -54.81%. The company's net income was $-227M, beating the average estimation of $-190M by 19.42%. Apple's SG&A was $213.89M, missing the average forecast of $351.75M by -39.19%. Lastly, the company's EPS was $-1.18, beating the average prediction of $-1.024 by 15.28%. In terms of the last quarterly report (Sep 2023), BioCryst Pharmaceuticals's revenue was $86.74M, beating the average analysts' forecast of $86.06M by 0.79%. The company's EBITDA was $-7.737M, missing the average prediction of $-66.044M by -88.29%. BioCryst Pharmaceuticals's net income was $-36.149M, missing the average estimation of $-50.574M by -28.52%. The company's SG&A was $50.65M, missing the average forecast of $112.97M by -55.17%. Lastly, the company's EPS was $-0.19, missing the average prediction of $-0.245 by -22.45%